<DOC>
	<DOCNO>NCT01394016</DOCNO>
	<brief_summary>The purpose study determine safe dose LY2835219 give participant advance cancer determine side effect may associate LY2835219 population . Efficacy measure use ass activity LY2835219 population .</brief_summary>
	<brief_title>A Phase 1 Study LY2835219 In Participants With Advanced Cancer</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<criteria>For Parts ( Dose escalation expansion ) : The participant must , judgment investigator , appropriate candidate experimental therapy either available standard therapy cease provide clinical benefit ( Parts A , B , C , D , E F ) combination fulvestrant ( Part G ) For Dose Escalation ( Part A ) : The participant must histological cytological evidence cancer , either solid tumor lymphoma , advance and/or metastatic For Dose Expansion ( Parts B , C , D , E , F G ) : The participant must histological cytological evidence one follow cancer : Part B : Nonsmall cell lung cancer subtype advance and/or metastatic Part C : Glioblastoma multiforme progress recurred radiotherapy and/or chemotherapy Part D : Breast cancer advance and/or metastatic Part E : Melanoma advance and/or metastatic Part F : Colorectal Cancer Part G : Breast Cancer advance and/or metastatic also hormone receptor positive As defined Response Evaluation Criteria Solid Tumors ( RECIST 1.1 ) Revised Response Criteria Malignant Lymphoma For Parts A G : Have measurable nonmeasurable disease For Parts B , C , D , E F : Have measurable disease Have give write informed consent prior studyspecific procedure Have adequate hematologic , hepatic , renal function Have performance status less equal 1 Dose Escalation ( Part A ) less equal 2 Dose Confirmation ( Parts B , C , D , E , F G ) Eastern Cooperative Oncology Group ( ECOG ) scale Have discontinue previous therapy cancer ( include chemotherapy , radiotherapy , immunotherapy , investigational therapy ) exception fulvestrant ( Part G ) least 21 day myelosuppressive agent 14 day nonmyelosuppressive agent prior receive study drug , recover acute effect therapy ( treatment relate toxicity resolve baseline ) except residual alopecia Are reliable willing make available duration study willing follow study procedure Males female reproductive potential must agree use medically approve contraceptive precaution trial 3 month follow last dose study drug Females child bear potential must negative serum pregnancy test within 3 day first dose study drug Have estimate life expectancy great equal 12 week Are able swallow capsule Have receive treatment drug receive regulatory approval indication within 14 21 day initial dose study drug nonmyelosuppressive myelosuppressive agent , respectively Have personal history follow condition : presyncope syncope either unexplained cardiovascular etiology , ventricular arrhythmia ( include limit ventricular tachycardia ventricular fibrillation ) , sudden cardiac death sudden cardiac arrest Have serious preexist medical condition , judgment investigator , would preclude participation study ( example , history major surgical resection involve stomach small bowel ) For Dose Escalation ( Part A ) : Have central nervous system ( CNS ) malignancy metastasis For Dose Confirmation ( Parts B , D , E , F G ) : Have CNS metastasis radiographically clinically unstable less 14 day prior receive study drug , regardless whether receive corticosteroid For Dose Confirmation ( Part C ) : Have glioblastoma multiforme radiographically clinically unstable less 14 day prior receive study drug , regardless whether receive corticosteroid Have acute leukemia Have receive autologous allogeneic stemcell transplant within 75 day initial dose study drug Females pregnant lactate Have active bacterial , fungal , and/or know viral infection ( example , human immunodeficiency virus [ HIV ] antibody , hepatitis B surface antigen [ HBSAg ] , hepatitis C antibody ) Screening require enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>